| Ashleigh Mangus, | |
|
4015 Interstate 45 N Suite 330 Ste 330, Conroe, TX 77304-3249 | |
| (936) 539-4700 | |
| Not Available |
| Full Name | Ashleigh Mangus |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 4015 Interstate 45 N Suite 330 Ste 330, Conroe, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548770787 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | AP134559 (Texas) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | AP134559 (Texas) | Primary |
| Entity Name | Texas Ear, Nose & Throat Specialists, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255314985 PECOS PAC ID: 5799770202 Enrollment ID: O20040415000492 |
News Archive
Salk scientists have identified a unique molecular signature in induced pluripotent stem cells (iPSCs), "reprogrammed" cells that show great promise in regenerative medicine thanks to their ability to generate a range of body tissues.
Sanofi-aventis has announced that the Cardiovascular and Renal Drugs Advisory Committee voted 10 to 3 in favor of the approval of Multaq by the U.S. Food and Drug Administration (FDA) to treat patients with non-permanent atrial fibrillation (AF).
The U.S. Senate last night passed the "Improving Access to Clinical Trials Act" (I-ACT), a bipartisan piece of legislation championed by the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.The legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits.
Bariatric surgery, which is best known for its ability to help patients lose substantial weight, can also result in significant improvement in nonalcoholic fatty liver disease (NAFLD), according to new research presented today at Digestive Disease Week- (DDW).
Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive's high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry.
› Verified 5 days ago
| Entity Name | Aj Marshall Medical Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669181707 PECOS PAC ID: 8325418106 Enrollment ID: O20230112001826 |
News Archive
Salk scientists have identified a unique molecular signature in induced pluripotent stem cells (iPSCs), "reprogrammed" cells that show great promise in regenerative medicine thanks to their ability to generate a range of body tissues.
Sanofi-aventis has announced that the Cardiovascular and Renal Drugs Advisory Committee voted 10 to 3 in favor of the approval of Multaq by the U.S. Food and Drug Administration (FDA) to treat patients with non-permanent atrial fibrillation (AF).
The U.S. Senate last night passed the "Improving Access to Clinical Trials Act" (I-ACT), a bipartisan piece of legislation championed by the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.The legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits.
Bariatric surgery, which is best known for its ability to help patients lose substantial weight, can also result in significant improvement in nonalcoholic fatty liver disease (NAFLD), according to new research presented today at Digestive Disease Week- (DDW).
Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive's high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashleigh Mangus, 10740 N Gessner Rd, Houston, TX 77064-1240 Ph: (281) 897-0416 | Ashleigh Mangus, 4015 Interstate 45 N Suite 330 Ste 330, Conroe, TX 77304-3249 Ph: (936) 539-4700 |
News Archive
Salk scientists have identified a unique molecular signature in induced pluripotent stem cells (iPSCs), "reprogrammed" cells that show great promise in regenerative medicine thanks to their ability to generate a range of body tissues.
Sanofi-aventis has announced that the Cardiovascular and Renal Drugs Advisory Committee voted 10 to 3 in favor of the approval of Multaq by the U.S. Food and Drug Administration (FDA) to treat patients with non-permanent atrial fibrillation (AF).
The U.S. Senate last night passed the "Improving Access to Clinical Trials Act" (I-ACT), a bipartisan piece of legislation championed by the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.The legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits.
Bariatric surgery, which is best known for its ability to help patients lose substantial weight, can also result in significant improvement in nonalcoholic fatty liver disease (NAFLD), according to new research presented today at Digestive Disease Week- (DDW).
Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and collaborators will be presenting five studies demonstrating how Adaptive's high-throughput sequencing platform enables diagnosis, detection and assessment of prognosis in hematological malignances and has increased sensitivity over flow cytometry.
› Verified 5 days ago